Division of Sosei Heptares
Latest From Sosei Inc.
Already having launched several portfolio companies, Roivant goes a step further by spinning out CNS specialist Arvelle from Axovant. BI and IBM will incorporate blockchain technology in clinical trials, while AbbVie licenses multiple myeloma candidate from TeneoBio.
Juno Therapeutics Inc. has followed in the footsteps of some of its big pharma rivals, Novartis and AstraZeneca, by acquiring RedoxTherapies, Inc. for its small molecule adenosine A2a (A2a) receptor antagonist vipadenant.
David Chiswell has worked tirelessly to build up the British biotech industry for over 30 years. Now, as CEO of Kymab, he is looking to the future of the industry and how to find the stars of the future.
The latest drug development news and highlights from our FDA Performance Tracker.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.